Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
While much has been written about the distinctions between biologics and small molecules in terms of their scientific, manufacturing and regulatory experiences, relatively little has been published comparing their clinical and commercial experiences. Employing a data base encompassing all 96 biol...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Bureau of Economic Research
2011
|
| Online Access: | http://hdl.handle.net/1721.1/62181 https://orcid.org/0000-0002-6388-0768 |